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Abstract
Crimean-Congo hemorrhagic fever virus (CCHFV) causes severe acute human disease
with lethal outcome. The knowledge about the immune response for this human health
threat is highly limited. In this study, we have screened the glycoprotein of CCHFV for novel
linear B-cell epitopic regions using a microarray approach. The peptide library consisted of
168 synthesized 20mer peptides with 10 amino acid overlap covering the entire glycopro-
tein. Using both pooled and individual human sera from survivors of CCHF disease in Tur-
key five peptide epitopes situated in the mucin-like region and GP 38 (G15-515) and GN
G516-1037 region of the glycoprotein were identified as epitopes for a CCHF immune
response. An epitope walk of the five peptides revealed a peptide sequence located in the
GN region with high specificity and sensitivity. This peptide sequence, and a sequence
downstream, reacted also against sera from survivors of CCHF disease in South Africa. The
cross reactivity of these peptides with samples from a geographically distinct region where
genetically diverse strains of the virus circulate, enabled the identification of unique peptide
epitopes from the CCHF glycoprotein that could have application in development of diag-
nostic tools. In this study clinical samples from geographically distinct regions were used to
identify conserved linear epitopic regions of the glycoprotein of CCHF.
Author summary
Crimean-Congo hemorrhagic fever (CCHF) is a widespread disease caused by a tick-
borne virus belonging to the genus Orthonairovirus of the Nairoviridae family. The virus
is responsible for outbreaks of severe viral hemorrhagic fever with a case fatality rate of
approximately 30%. The CCHF virus is transmitted to people either by tick bites or
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through contact with infected animal blood or tissues. A mouse brain-derived vaccine
against CCHF has been developed (included in this study) and used on a small scale in
eastern Europe. There is no safe and effective vaccine widely available for human use. Cur-
rently, there are a limited number of serological assays commercially available for testing
for CCHFV specific IgG and IgM. There are enzyme linked immunosorbent assays
(ELISA) and imunnofluorescent assays (IFA) designed for screening human samples for
diagnostic purposes however they are not cost effective for surveillance studies. The limit-
ing factor for the replication of these protocols in other laboratories is the availability of
antigens and (where relevant) specified monoclonal antibodies. To contribute to the
improvement of the diagnostic methods for CCHFV, we aimed to identify and character-
ize new synthetic antigens that were more sensitive and specific and could be applied in
epidemiologic surveys.
Introduction
Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne viral zoonosis distributed
in Africa, Asia, eastern Europe and the Balkans. Ticks belonging to the genus Hyalomma are
considered the principal vectors and the broad geographic distribution of the virus correlates
with that of the vector [1,2]. More recently the virus has been identified as a cause of human
disease in Spain [3], Greece [4], and India [5]. There is growing concern that the virus could
emerge in other southern European countries which are within the distribution range of the
vector [6,7]. The virus causes a disease that ranges in severity for reasons that are not clear [1,
2]. Fatality rates vary depending on the severity of the disease and can be as high as 30% in
some countries.
Current diagnosis of CCHFV is based on the detection of viral RNA using RT-PCR, isola-
tion of the virus and/or IgM/IgG detection [8,9]. Hence the detection of an antibody response
against CCHFV is important for diagnosis as well as seroprevalence studies. Currently, most
reagents used for development of diagnostic tools are dependent on culturing the virus within
the confines of a biosafety level 4 facility. The biosafety considerations limit the number of lab-
oratories which are able to prepare reagents [10]. The current perceived risk of spread of the
virus to non-endemic regions highlights the importance of increasing diagnostic capacity and
serological surveillance using safe, standardized reagents [9].
The viral genome consists of three RNA segments designated small (S), medium (M) and
large (L). The S segment encodes the nucleocapsid, while the L segment translates into the
RNA polymerase. The M segment encodes for a glycoprotein precursor that is post-transla-
tionally cleaved and generates mature GN and GC and a mucin-like domain [11]. Serological
assays have been developed based on the recombinant nucleocapsid protein [8] but the use of
glycoproteins has not been extensively investigated possibly due to the inherent challenges
associated with preparing recombinant glycoproteins. However, peptides mimicking epitopic
regions could have a potential as diagnostic tools and if the epitopes induce protective immu-
nity they could play a role in vaccine development [12]. Goedhals et al. identified two possible
epitopic regions in the GC of CCHFV [13] which could have potential in further development
of serological assays and warrant further investigation.
In this study we used a microarray technique creating a high throughput and cost effective
method to screen B-cell peptide epitopes [14–16] covering the complete glycoprotein precur-
sor of CCHFV. This is the first study using microarray technology to screen clinical samples
from survivors of CCHF infections in South Africa and Turkey. This data was also further
CCHFV B-cell epitopes
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examined using serum samples from vaccinated individuals that received the Bulgarian vac-
cine. Interestingly, we have identified several specific peptide sequences which may have appli-
cation in development of serological assays and also in vaccine development.
Materials and methods
Solid Phase Peptide Synthesis (SPPS)
Overlapping peptides representing the complete glycoprotein precursor of a strain of CCHFV
including the O-glycosylated mucin-like domain and GP38 at amino acid positions 15–515,
GN and NSM (515–1037) and GC (1037–1688) (strain Turkey-Kelkit06, uniprot #C7F6X8)
were prepared by a modified automated Fmoc-SPPS (Solid-Phase Peptide Synthesis) method-
ology on a Syro II peptide synthesizer (MultiSynTech, Witten, Germany) as described previ-
ously [17,18]. All samples were screened against a peptide library representing a CCHFV
isolate from Turkey to identify conserved epitopic regions between different lineages.
Printing of microarrays
Peptides were selectively enriched by covalent immobilization onto amine reactive N-hydroxy
succinimide activated hydrogel coated MPX16 glass slides (Schott Nexterion, SlideH) with a
BioRobotics MicroGrid II spotter (Genomics Solution) using Stealth 3B Micro Spotting Pins
(ArrayIt) with approximately 6 nL per spot as described previously [17,18]. Printed glass slides
were humidified for 30–60 min before N-hydroxy succinimide deactivation in blocking buffer
(50 mM ethanolamine in 50 mM sodium borate, pH 8.5) for 30 min, then rinsed quickly in
water and spun dry (VWR, Galaxy MiniArray). The blocked glass slides were fitted into super-
structures; 2/16/48 well (FAST FRAME, Schleicher & Schuell (Whatman)) to make separate
identical peptide libraries. To each library either 500/100/10 μL PLI-P (0.5 M NaCl, 3 mM
KCl, 1.5 mM, KH2PO4, 6.5 mM Na2HPO4, pH 7.4, 3% bovine serum albumin (BSA) was
added dependent on the superstructure.
On-slide glycosylation of peptides
Blocked slides were fitted with a 2-well superstructure (FAST FRAME, Schleicher & Schuell
(Whatman)) to form 2 wells. The wells were filled with 500 μL of glycosylation mixture (10 μL
of 100 mM UDP-GalNAc (Sigma-Aldrich), 10 μL of either 0.36 mg/mL mM GalNAc-transfer-
ase 2 [GalNAc-T2] (SBH Biosciences) or 0.46 mg/mL GalNAc-transferase 3 [GalNAc-T3]
(SBH Biosciences) 10 mM and 480 μL HEPES buffer, placed in a humidification chamber, and
incubated for two hours at room temperature (RT). Slides were then washed with 0.1 M
AcOH (2 x 5 min, shaking) and PLI-P (5 min, shaking). Slides were again washed with phos-
pate buffered saline (PBS) pH7.4, rinsed thoroughly with water, dried by centrifugation, and
were then ready to be immediately used in a subsequent lectin binding experiment [15,17].
Slides were incubated with biotinylated VVA lectin (1:500 dilution in PLI-P buffer) for 1 hour
at RT, followed by incubation with streptavidin-AlexaFluor 647 (1:1000 dilution in PLI-P) for
1 hour.
Immunscreening using peptide assays
Pooled (to conserve resources) or individual CCHFV IgG antibody positive sera and CCHFV
IgG negative sera or serum samples IgG positive for varicella zoster virus (VZV), Epstein-Barr
virus (EBV), herpes simplex virus (HSV) and tick-borne encephalitis (TBE) were diluted (1:10,
1:20, 1:25, 1:50) in incubation buffer PLI-P (0.5 M NaCl, 3 mM KCl, 1.5 mM KH2PO4, 6.5 mM
Na2HPO4, pH = 7.4, 3% BSA), added directly onto slide subarrays and incubated for minimum
CCHFV B-cell epitopes
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1 h (up to 2 days) on a shaking plate with a slow rotation. Slides were washed three times using
PBS. Positive reactors were detected using goat anti-human IgG-Cy3 (Fc specific, 10μg/mL,
Sigma-Aldrich) diluted (1:1000) in PLI-P. After the final wash, slides were spun dry and
scanned followed by image analysis. Slides were scanned using a ProScanArray microarray
scanner (Perkin Elmer) equipped with laser for excitation at 543 nm and images were analyzed
with Scan Array Express software. Spots were identified using automated spot finding with
manual adjustments for irregularities in print. The final data was obtained from the mean spot
Relative Fluorescence Units (RFU) from all replicate spots for each sample (3 or 5 spots). Spot
intensities were determined by subtracting the median pixel intensity of the local background
from the average pixel intensity within the spot. The quality control covered intra- and inter-
chip quality analysis of replicates. For the selected peptides, serum samples with relative fluo-
rescent values higher than two standard deviations over the mean of the control group were
designated as positive.
Patient sera
The samples were routinely heated at 56˚C for 1 hour prior to handling. All antibody positive
samples used in the study were from convalescent or vaccinated individuals and hence would
be negative for CCHFV.
Turkey. A total of 30 CCHF IgG positive sera from Refik Saydam National Public Health
Agency, Ankara, Turkey were included in the study. All samples were confirmed CCHF IgG
antibody positive using a commercial ELISA (Vektor-Best, Novosibirsk, Russia). Ethics
approval was obtained for samples collected from patients in Turkey (Ethics approval number
2009–0728).
Bulgaria. The study included eight samples obtained from medical personnel who
were voluntarily vaccinated in order to produce hyperimmune gamma-globulin. Of the
ten participants, seven were female and three male, and their age ranged from 30 to 55
years (median age 48). The first group of four participants (individuals 1–4) had received
several vaccinations and blood samples were taken one month after the last immunization.
The second group of four participants (individuals 5–8) that had just completed a full vac-
cination program (consisting of three doses, plus one last dose one year after the first
dose) and blood samples were taken one month after the last dose (Ethics approval number
2/2011).
South Africa. A total of 41 CCHF IgG positive sera from 14 laboratory confirmed patients
in South Africa were included in the study. Serum samples were collected at intervals ranging
from several months after infection up to 12 years after illness. All samples were confirmed
CCHF IgG antibody positive using a commercial immunofluorescent antibody assay (EuroIm-
mune). In addition, 11 CCHF IgG negative sera from 11 healthy volunteers were included as
controls samples. Ethics approval was obtained for samples collected from patients in South
Africa (Ethics Committee number 152/06).
Control sera. 37 clinically validated sera from individuals infected with other viral dis-
eases such as TBE, (n = 9), EBV, (n = 10) [16] and HSV, (n = 9) [15,19] and VZV, (n = 9) [19]
were included in the study.
Ethical statement. Ethics approval was obtained for samples collected from patients in
Turkey, Bulagria, South Africa (Ethics approval numbers 2009–0728 (Turkey), 2/2001 (Bul-
garia)ECUFS 152/06 (South Africa). All participants (Turkey, Bulgaria and South Africa)
were adults. Written informed consent was obtained from participants. All the collected
samples were derived from blood donors and anonymized at the hospital/institute where
CCHFV B-cell epitopes
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the samples were originally collected, i.e. without possibility to trace samples back to the
donor.
Statistical analysis
All the data represented in this study are mean values from 3–5 replicates. The final data was
obtained from the mean spot Relative Fluorescence Units (RFU) from all replicate spots for
each sample (3 or 5 spots). Spot intensities were determined by subtracting the median pixel
intensity of the local background from the average pixel intensity within the spot. The quality
control covered intra- and interchip quality analysis of replicates. For the selected peptides,
serum samples with relative fluorescent values higher than two standard deviations over the
mean of the control group were designated as positive. A One-way-ANOVA (Prism Graphpad
7 software) was conducted as needed.
Results
Reactivity of serum samples collected from survivors in Turkey
A scan peptide library consisting of 168 peptides (20mer with a 10 amino acid overlap, see
S1 Table) representing the glycoprotein precursor which includes the mucin-like domain,
GP38, and GN and GC region of a strain of CCHFV from Turkey, was incubated with pooled
inactivated sera from survivors of CCHFV infection. Reactivity against peptides represent-
ing possible epitopic regions were identified (Fig 1). Samples with a relative fluorescent
value greater than two standard deviations above the mean of the control group were desig-
nated as positive.
Sera from survivors of CCHFV reacted significantly against fourteen peptides (entry 1–14,
Table 1). Although there was minor reactivity from control sera against some peptides (entry
15–20, Table 1), the relative fluorescent values for these sera were significantly lower and these
reactions were considered non-specific. From the results of this initial screen, 32 peptides were
selected based on a combination of high reactivity of CCHFV positive sera and low reactivity
of control sera (S2 Table) and narrowed down the selection to the five most promising peptide
Fig 1. Reactivity of pooled Turkish sera. Reactivity of eight CCHFV survivor pools (blue) and six uninfected pools (black) against
168 peptides representing the complete precursor glycoprotein of CCHFV (Turkish strain, Kelkit06, Uniprot #C7F6X8).
https://doi.org/10.1371/journal.pntd.0006598.g001
CCHFV B-cell epitopes
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epitopes (entry 6, 7, 12, 13 and 14, (Table 1)). To further map the epitopes with respect to pep-
tide sequence, a stepwise single-amino-acid epitope walk library of 20mers of these peptides
was synthesized [15].
Six CCHFV IgG positive and two CCHFV IgG negative sera were analyzed individually, as
shown in Fig 2. Overall, serum reactivities were high (>50%) against each peptide 20mer
sequence. Two different reactivity patterns were apparent when screening the epitopes
Table 1. Sequences of scan peptides that showed significant reactivity with pooled Turkish sera of CCHFV survivors (1–14) and with control sera (15–20). Five pos-
sible epitopes (6, 7, 12, 13 and 14) were selected for further evaluation using a single-amino acid epitope walk analysis.
ID Peptide Sequence
1 p14 131TSPSSSPSTPSTPQGIYHPA150
2 p15 141STPQGIYHPARSLLSVSSPK160
3 p19 181HSAMSRIPTPHTATRVSTEN200
4 p22 211SSAQQTTPSPMTSPAQSILL230
5 p23 221MTSPAQSILLMSAAPTAVQD240
6 p24 231MSA APTAVQDIHPSPTNRSK250
7 p55 541ETAEIHDDNYGGPGDKITIC560
8 p56 551GGPGDKITICNGSTIVDQRL570
9 p78 771RLTSDGLARHVTQCPKRKEK790
10 p96 951NVMLAVCKRMCFRATIEASR970
11 p99 981TTFVICILTLTICVVSTSAV1000
12 p105 1041RKPLFLDSIVKGMKNLLNST1060
13 p107 1061SLETSLSIEAPWGAINVQST1080
14 p156 1551PQSILIEHKGTIIGKQNDTC1570
15 p51 501SVLRQYKTEIKIGKASTGFR520
16 p64 631VLDACDSSCEVMIPKGTGDI650
17 p74 731QYRELKPQTCTICETAPVNA750
18 p91 901CSIGSVNGFEIESHKCYCSL920
19 p164 1631RRTRGLFKYRHLKDDEETGY1650
20 p165 1641HLKDDEETGYRRIIERLNSK1660
https://doi.org/10.1371/journal.pntd.0006598.t001
Fig 2. Epitope walk (EW) of selected five peptides (p24, p55, p56, p78 and p96). Figure illustrates the RFU of individual serum samples from CCHFV survivors from
Turkey to selected peptides. Epitope walk sequences are found in S3 Table. In general two different patterns were seen when screening the epitopes (colored in blue and
orange).
https://doi.org/10.1371/journal.pntd.0006598.g002
CCHFV B-cell epitopes
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(colored in blue and orange in Fig 2). Four serum samples (designated CCHFV 1–4, blue
lines) reacted strongly with early epitope walk (EW) peptides within libraries p24 and p55+56.
In contrast, serum samples designated CCHFV 5 and 6 (orange) reacted weakly with these
peptides, or not at all, and reacted strongly with peptide 40 within library p55+56 and peptide
64 in p78. The six serum samples reacted uniformly with p78 (EW 57–61) and p96 (EW 80–
86). No reactivity was detected using the serum samples that were negative for CCHF IgG anti-
body (uninfected, black lines). High reactivity was seen against epitope walk (EW) residues
25–32 (p55+56) for four serum samples (CCHFV 1, 2, 3 and 4), whereas the remaining sam-
ples (orange) reacted against EW peptide 40 (p55+56). All sera reacted against EW peptides
81–86 within p96.
High reactivity was seen against epitope walk (EW) residues 25–32 (p55) for four serum
samples CCHFV 1, 2, 3 and 4 (blue), whereas the remaining samples (orange) reacted
against EW peptides 40 (p56). All sera reacted against EW peptides p81-86 derived from
p96.
Additional validation of p96 and its derived epitope walk peptides was performed with 30
sera from survivors of CCHFV from Turkey and 37 sera from individuals infected with other
viral diseases such as TBE, VZV, EBV and HSV (Fig 3). The results demonstrate that the
CCHFV infected individuals show high specificity and sensitivity (97%) to epitope p96. In
addition, the activity of 10 sera from individuals vaccinated with the Bulgarian CCHFV vac-
cine [20] with p96 was analysed. This experiment also demonstrated that the vaccinated indiv-
duals have significant reactivity towards this novel epitope p96 whereas the control sera
(n = 37) showed no reactivity. The amini acid similarity between strains from Turkey and Bul-
garian is high and the epitopic region identified has only minor differences which indicates
Fig 3. Dot-plot of intensities of the selected peptide EWP 83 (p96 + 3 aa, 954LAVCKRMCFRATIEASRRAL973)
after serology. This includes sera from Turkish CCHFV survivors, control sera from individuals infected with other
viral pathogens as controls and Bulgarian individuals vaccinated against CCHFV. The dotted line represents the
diagnostic cut-off value determined from mean of the control group plus two standard deviations. P<0.0001.
https://doi.org/10.1371/journal.pntd.0006598.g003
CCHFV B-cell epitopes
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that a similar reactivity towards this epitope could be expected. An analysis of variance showed
that the reactivity of samples from Turkish survivors and from the vaccinated group relative to
the control group was highly significant (F(2,74) = 68, P<0.0001).
Lastly, since glycosylation can be important for viral envelope proteins and inducing
immune responses, microarray experiments were conducted to determine whether additional
epitopes could be identified using glycosylated peptides. Peptides immobilised on slides were
treated with ppGalNAc transferase 2 (T2) and ppGalNAc transferase 3 (T3), as described pre-
viously [15]. Glycosylation of peptides that represent parts of the mucin-domain were glycosy-
lated as predicted with Net-O-Glyc (v3.1) algorithm. (S1 Fig). We did not observe any
additional reactivity of the CCHFV sera after on-chip glycosylation of the peptides. However,
one should have in mind that these data are based on peptide glycosylation experiments which
may not mimic the natural glycosylation pattern on the envelop proteins.
Reactivity of serum samples collected from survivors in South Africa
To further evaluate the identified peptide epitopes, a cohort of sera from survivors of CCHFV
in South Africa were screened for reactivity against the 168 20mer peptide library. A total of 41
CCHF IgG positive sera from 14 laboratory confirmed patients in South Africa were included
in the study. All samples were confirmed to be CCHF IgG antibody positive using a commer-
cial immunofluorescent antibody assay (EuroImmune). In addition, 11 CCHF IgG negative
sera from 11 healthy volunteers were included as control samples. Pooled serum samples from
confirmed patients reacted against peptides p55, p56, p105, p115, p119, p127 and p168 (Fig 4).
Reactivity against peptides 119, 127 and 168 was unique to these sera.
Single serum sample experiments were performed using a 108 peptide sublibrary (see S1
Table, 1–108) from the larger 168 peptide library. As seen with the Turkish cohort of sera, the
majority of the South African serum samples (97,6%) reacted against the p55 (ETAEIHDD-
NYGGPGDKITIC) (Fig 5). The specificity was even more pronounced for the South African
sera. An analysis of variance showed that the reactivity of samples from Turkish survivors and
SA survivors relative to the control group was highly significant (F(2,81) = 11, P<0.0001).
Nine peptides were identified which included a region that reacted against either Turkish
or South African samples or reacted against both samples (Table 2). Finally the predicted
Fig 4. Reactivity of pooled South African sera. Four CCHFV survivor pools (red) and one uninfected pool (black)) against 168 peptides representing
the complete precursor glycoprotein of CCHFV (Turkish strain).
https://doi.org/10.1371/journal.pntd.0006598.g004
CCHFV B-cell epitopes
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amino acid sequences for each peptide region were retrieved from UniProt and aligned to
identify similarities between the geographically distinct isolates of the virus (Table 3). This
high coverage of same peptide reactivity can be explained by high amino acid conservation
along the selected epitopes (Table 3). In contrast the alignment confirms up to four mis-
matches in the predicted amino acid sequence between the Turkish peptide sequence and the
Fig 5. Dot-plot of intensities of the selected peptide 55 (541ETAEIHDDNYGGPGDKITIC560) after serology. This
included sera from Turkish CCHFV survivors, control sera from individuals infected with other viral pathogens as
controls and Bulgarian indivduals vaccinated against CCHFV. The dotted line represents the diagnostic cut-off value.
P<0.0001.
https://doi.org/10.1371/journal.pntd.0006598.g005
Table 2. Reactivity of Turkish (n = 30) and South African sera (n = 41) against nine selected peptides.
Peptide Negativea Positiveb Positive x5b Positive x10b % Positive
Turkey SAc Turkey SA Turkey SA Turkey SA Turkey SA
24 20 29 10 12 2 1 0 0 33 29
24 EW27 7 23 12 1 77
55 12 1 18 40 10 22 3 18 60 98
56 16 17 14 24 6 5 3 2 47 59
78 27 15 3 26 1 3 0 0 10 63
79 25 16 10 6 39
95 26 15 0 0 37
96 23 33 7 8 0 0 0 0 23 20
96 EW83 1 29 0 0 97
96 EW84 2 28 10 0 93
105 14 27 15 5 66
107 30 11 3 0 27
a values below 2 average of uninfected patient sera reactivity.
b Positive x5/x10 indicated values 5/10 times above cut-off value.
c South Africa
https://doi.org/10.1371/journal.pntd.0006598.t002
CCHFV B-cell epitopes
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South African sequence for p96, thus possibly explaining their difference in reactivity of geo-
graphically diverse samples against this peptide.
The combination of p55/p56 (ETAEIHDDNYGGPGDKITIC/GGPGDKITICNGSTIVD
QRL) with p96 (NVMLAVCKRMCFRATIEASR) represents an immunodominant epitopic
region that would result in a multiepitope covering the majority of the Turkish and South Afri-
can strains, due to minimal differences in the amino acid sequence along the defined epitopes,
defined (Fig 6). An analysis of variance showed that the reactivity of samples from Turkish sur-
vivors and SA survivors and relative to the control group was highly significant (F(3,107) = 11,
P<0.0001).
Discussion
CCHFV is considered an emerging pathogen particularly in southern and eastern European
countries. The emergence of this virus has significant public health implications. Currently
there are a limited number of laboratories that can prepare reagents for diagnosis and serologi-
cal surveillance as culturing the virus requires maximum containment facilities. Development
of safe reagents will play a role in building capacity for diagnosis and surveillance. Develop-
ment of reagents must take into consideration the global diversity of CCHFV. In this study
peptides were used to identify potential epitopic regions on the glycoprotein precursor of an
isolate from Turkey.
The initial screen was peformed using a total of 168 peptides representing the entire GP of a
Turkish strain of CCHFV. Five peptides were selected for further investigation using epitope
walk analysis in an attempt to identify specific peptide sequence mimicking immunodominant
linear epitopes. Despite some variability in the reactivity of the samples from survivors in Tur-
key, common regions were identified within p96 and p55+56. Variability in the responses was
particularly noted against the peptides of p24. The differentiated response to the EW peptides
of p24 is most likely caused by the fact that p24 is located in the mucin-like region of the enve-
lope protein which is highly glycosylated. The glycosylation of the mucin-like region can differ
Table 3. Strain similarity, comparison of amino acid sequences from eight strains of CCHFV from South Africa and one strain of CCHFV from Turkey. Sequence
data was retrieved from UniProt. Amino acid differences are bolded.
Strain Uniprot nr p55 p56
Turkey C7F6X8 ETAEIHDDNYGGPGDKITIC GGPGDKITICNGSTIVDQRL
SA SPU431/85 A0A068JCA2 ETTEIHSDNYGGPGDKITIC GGPGDKITICNGSTIVDQRL
SA SPU383/87 A0A068JFM1 ENAEIHSDNYGGPGDKITIC GGPGDKITICNGSTIVDQRL
SA SPU130/89 A0A068JC98 ENAEIHSDNYGGPGDKITIC GGPGDKITICNGSTIVDQRL
SA SPU497/88 A0A068JD49 ENAEIHSDNYGGPGDKITIC GGPGDKITICNGSTIVDQRL
SA SPU45/88 A0A068JCX3 ENTEIHSDNYGGPGDKITIC GGPGDKITICNGSTIVDQRL
SA SPU187/90 A0A068JCX6 ETAEIHGDNYGGPGDKITIC GGPGDKITICNGSTIVDQRL
SA SPU48/90 A0A068JD54 ETAEIHGDNYGGPGDKITIC GGPGDKITICNGSTIVDQRL
Strain Uniprot nr p78 p96 p105
Turkey C7F6X8 RLTSDGLARHYTQCPKRKEK NVMLAVCKRMCFRATIEASRRALLIR RKPLFLDSIVKGMKNLLNST
SA SPU431/85 A0A068JCA2 RLTSDGLARHVMQCPKRKEK NVMLAVCKRMCFRATIEVSNRALLIR RKPLFLDSIVKGRKNLLNST
SA SPU383/87 A0A068JFM1 RLTSDGLARHVIQCPKRKEK NVMLAVCKRMCFRATVEVSNKALLIR RKPLFLDSIVKGMKNLLNST
SA SPU130/89 A0A068JC98 RLTSDGLARHVMQCPKRKEK NVMLAVCKRMCFRATVEVSNKALLIR RKPLSLDSIVKGMKNLLNST
SA SPU497/88 A0A068JD49 RLTSDGLARHVMQCPKRKEK NVMLAVCKRMCFRATVEVSNKALLIR RKPLFLDSIVKGMRNLLNST
SA SPU45/88 A0A068JCX3 RLTSDGLARHVMQCPKRKEK NVMLAVCKRMCFRATMEVSSKALLIR RKPLFLDSIVKGKKNLLNST
SA SPU187/90 A0A068JCX6 RLTSDGLARHVTQCPKRKEK NVMLAVCKRMCFRATMEVSNRALFIR RRPLFLDSIVKGMKNLLNST
SA SPU48/90 A0A068JD54 RLTSDGLARHVTQCPKRKEK NVMLAVCKRMCFRATMEVSDRALFIR RKPLFRDSIVKGMKNLLNST
https://doi.org/10.1371/journal.pntd.0006598.t003
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and it is therefore expected that the serum response to the naked peptides will be diverse [16].
The role of the mucin-like domain in stimulation of B cells during CCHF infections has not
been well defined. By analogy with Ebola virus the mucin-like domain may block access to GP
and actually inhibit immune responses [21]. However as the mucin-like domain is not incor-
porated into viral particles its role may be very different to that proposed for Ebola [11]. It
would be useful to determine if the mucin-like domain is involved in immune evasion and if
deletion of this region promotes an immune response to more conserved regions on the GP as
has been shown for Ebola virus. This would be significant for vaccine development but less
important for developing tools for detection of antibody responses.
In all the experiments p55 was identified as the top candidate due to the strong response
shown when incubated with serum from CCHFV infected patients. The experiments with
pooled sera showed a very dominating RFU signal, thereby undermining some of the other
binding when reading the scan. The reaction towards p55 was scattered with around 2/3 of the
samples binding to the peptide significantly where minor to no binding was seen in other
serum samples. In the second group of sera (orange pattern) the highest reaction was shifted
by 10 aa residues towards p56 in comparison to the blue pattern. A small common epitope was
identified in p78 (EW 57–61) with all serum samples showing similar reactivity. This epitope
could be of potential interest due to the homogenous binding. The response to this epitope
walk was lower than as seen with the other epitope walks except for CCHFV 5 and 6 which
reacted to EW peptide 64. The epitope with the strongest homogenous response was found in
p96 epitope walk representing sequences being close to the transmembrane region (aa 973–
997), and the tertiary structure can be expected to be more stable and should be in reach of B-
Fig 6. Dot-plot after combining intensities of serology with peptide p55 and p96 or EWP p83 (p96 + 3 aa). Control
sera from healthy individuals, Turkish CCHFV survivors and South African CCHFV survivors. The dotted line
represents the diagnostic cut-off value. P<0.0001.
https://doi.org/10.1371/journal.pntd.0006598.g006
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cells/antibodies/immune cells. All serum samples tested showed binding towards the peptides
EW peptides 80–86.
In summary, single amino acid shifts generated differentiation in reactivity patterns with
no major reactive single peptide epitope for p24, p55, p56 and p78, whereas library members
derived from p96 (epitope walk peptides p81-86, 951NVMLAVCKRMCFRATIEASRRAL-
LIR975) show reactivity with all six CCHFV sera. No reactivity towards these peptides was
observed with the two control sera.
Identification of peptides that are cross reactive serologically against geographically distinct
strains is important for development of standardised assays for detection with application on
different continents. Despite some variablity in the reactivity of samples from South African
patients, a commonality was identified in p55.
The result of the epitope walk indicated that a strong differentiated binder could be
obtained by combining the epitope 541ETAEIHDDNYGGPGDKITIC560 due to the strong sig-
nal of p55, with p96 (951NVMLAVCKRMCFRATIEASR970) for specific overall coverage. A
combinational multi-epitope including these peptides could eventually secure a strong selec-
tivity and sensitivity.
The study identified several specific peptide sequences which may have application in
development of serological assays and possibly vaccine development. However for vaccine
development it must be taken into consideration that the immune correlates of protection for
CCHFV are currently not well defined and the role of T cells and discontinuous B cell epitopes
would need to be considered. Evidence exists for a role for both antibody and T cell responses.
A long lived cytotoxic T cell response was recently described in survivors of infection suggest-
ing a role for T cells in protection [22]. However vaccine studies have suggested a role for both
humoral responses and T cell responses. Results from a candidate vaccine employing a modi-
fied vaccinia virus Ankara poxvirus vector containing the GP in which passive and adoptive
transfer of serum samples and T-lymphocytes were used in an attempt to define the role of
each arm of the adaptive immune response, concluded that protective immunity likely requires
both humoral and cellular involvement [23]. Serum samples collected from volunteers vacci-
nated using the inactivated Bulgarian vaccine reacted similarly to survivors of virus infection
from Turkey with regard to peptides recognised although there were differences in intensity of
reactivity. Sera from vaccinated individuals reacted with lower intensity than sera from natu-
rally infected survivors. Previous investigations of immune responses in vaccinated individuals
suggested that even after several boosters the neutralising antibody response was low.
Although it is not known if the epitopic regions identified in this study represent neutralising
epitopes it is possible that the lower reactivity is a reflection of a less robust immune response
in vaccinees compared with survivors.
The use of glycoproteins has not been extensively investigated for serological assays likely
due to the inherent challenges associated with expression of recombinant glycoprotein anti-
gens. NP has been investigated as a target for diagnostic proteins due to its immunogenicty,
abundance and homology between isolates. However although there is less sequence homology
in the M gene compared to the S gene encoding for NP, a significant amount of the diversity is
located within the mucin-like region with less than 10% amino acid diversity determined for
the remainder of the GP [24]. It is probable that epitopes inducing immunodominant and/or
neutralising responses are more likely to be conserved between isolates and in the absence of
detailed data regarding immunodominant epitopes in the GP it is appropriate to further define
if there are conserved regions with possible roles in development of diagnostic tools and incor-
poration in vaccine design. Peptides mimicking epitopic regions could have a potential as diag-
nostic tools [12]. Goedhals et al. identified two possible epitopic regions in the GC of CCHFV
and although in this study reactivity was identified in these epitopic regions using samples
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from South African survivors there was no significant reactivity from Turkish sera [13]. This
highlights the need to consider diversity when selecting peptides to mimic epitopic regions.
Differences in serological reactivity between Turkish and South African samples suggested
possible differences in protein sequences which were confirmed by alignment of predicted
amino acid sequences. Hence the use of multiple peptides in downstream assay development
will likely increase the usefulness of the assays. Lack of reactivity against serum samples col-
lected from patients with other infectious diseases that could be considered in a differential
diagnosis suggest that these peptides react more specifically against CCHFV antibodies. How-
ever the specificity and sensitivity will need to be validated in any future assay development.
The cross-reactivity of these peptides with samples from a geographically distinct region where
genetically diverse strains of the virus circulate enabled the identification of unique peptide
epitopes from the CCHFV glycoprotein that could have application in develoment of diagnos-
tic tools such as lateral flow or ELISA for antibody detection.
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